Stock IVBIY INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 07:31:58 01/04/2024 pm IST 		5-day change 1st Jan Change
19.48 USD +4.39% Intraday chart for Innovent Biologics, Inc. -.--% -6.75%
21/05 Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug MT
07/05 Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 29,957 96,872 57,482 45,398 63,018 57,619 - -
Enterprise Value (EV) 1 26,589 89,793 50,957 39,338 63,018 52,595 53,255 53,026
P/E ratio -16.3 x -93.3 x -18.2 x -20.3 x - -67.2 x 456 x 42.3 x
Yield - - - - - - 0.01% -
Capitalization / Revenue 28.6 x 25.2 x 13.5 x 9.96 x 10.2 x 7.6 x 5.79 x 4.45 x
EV / Revenue 25.4 x 23.4 x 11.9 x 8.63 x 10.2 x 6.94 x 5.35 x 4.1 x
EV / EBITDA -16.2 x -370 x -16.7 x -14.3 x -105 x -105 x 108 x 29.5 x
EV / FCF -13.1 x -113 x -16.5 x -14 x - -55.4 x -233 x 49.4 x
FCF Yield -7.64% -0.89% -6.06% -7.16% - -1.8% -0.43% 2.02%
Price to Book 5.87 x 10.7 x 5.54 x 4.11 x - 4.69 x 4.83 x 4.41 x
Nbr of stocks (in thousands) 12,62,562 14,02,776 14,62,109 15,34,407 16,21,831 16,27,102 - -
Reference price 2 23.73 69.06 39.31 29.59 38.86 35.41 35.41 35.41
Announcement Date 30/03/20 29/03/21 29/03/22 28/03/23 20/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,048 3,844 4,270 4,556 6,206 7,578 9,954 12,944
EBITDA 1 -1,638 -242.4 -3,045 -2,747 -600.1 -499.1 493.6 1,799
EBIT 1 -1,676 -310.4 -3,113 -3,066 - -928.1 110 1,612
Operating Margin -159.96% -8.08% -72.9% -67.29% - -12.25% 1.11% 12.45%
Earnings before Tax (EBT) 1 -1,720 -858.7 -3,051 -2,170 - -818.7 156.2 1,634
Net income 1 -1,720 -998.4 -3,138 -2,179 - -844.9 98.03 1,365
Net margin -164.2% -25.97% -73.5% -47.83% - -11.15% 0.98% 10.55%
EPS 2 -1.460 -0.7400 -2.160 -1.460 - -0.5270 0.0776 0.8368
Free Cash Flow 1 -2,030 -796.7 -3,090 -2,816 - -948.8 -228.8 1,072
FCF margin -193.83% -20.73% -72.38% -61.8% - -12.52% -2.3% 8.28%
FCF Conversion (EBITDA) - - - - - - - 59.59%
FCF Conversion (Net income) - - - - - - - 78.55%
Dividend per Share 2 - - - - - - 0.002860 -
Announcement Date 30/03/20 29/03/21 29/03/22 28/03/23 20/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 702 984.2 2,860 1,942 2,328 2,240 2,317 2,702 3,505 3,728 4,119
EBITDA - - - - - - - - - - -
EBIT 1 - - - -1,148 -1,960 -1,212 -1,617 -718.8 - -696.6 -1,025
Operating Margin - - - -59.12% -84.17% -54.11% -69.8% -26.61% - -18.69% -24.89%
Earnings before Tax (EBT) - - - - -1,876 -998.9 -1,172 -256.1 - - -
Net income - - - - -1,963 -950.5 -1,229 -139.1 - - -
Net margin - - - - -84.31% -42.43% -53.04% -5.15% - - -
EPS 2 -0.8400 -0.4600 -0.2800 -0.8100 -1.350 -0.6500 -0.8100 -0.0900 - -0.3000 -0.5100
Dividend per Share - - - - - - - - - - -
Announcement Date 30/03/20 26/08/20 29/03/21 25/08/21 29/03/22 25/08/22 28/03/23 23/08/23 20/03/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 3,368 7,079 6,525 6,059 - 5,024 4,364 4,593
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -2,030 -797 -3,090 -2,816 - -949 -229 1,072
ROE (net income / shareholders' equity) -38.4% -14.8% -32.8% -20.7% - -6.72% 0.61% 9.38%
ROA (Net income/ Total Assets) -25.8% -10.5% -22.4% -12.9% - -4.12% 0.61% 5.75%
Assets 1 6,672 9,533 14,039 16,916 - 20,507 16,075 23,744
Book Value Per Share 2 4.040 6.470 7.100 7.200 - 7.550 7.340 8.030
Cash Flow per Share 2 -1.410 -0.2300 -1.390 -1.290 - -0.2100 0.2300 1.030
Capex 1 366 489 1,066 897 - 708 740 783
Capex / Sales 34.93% 12.72% 24.96% 19.68% - 9.34% 7.43% 6.05%
Announcement Date 30/03/20 29/03/21 29/03/22 28/03/23 20/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Innovent Biologics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
35.41 CNY
Average target price
51.14 CNY
Spread / Average Target
+44.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-2.99% 89.49B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.50% 40.67B
BIOGEN INC. Stock Biogen Inc.
-12.01% 33.15B
UCB Stock UCB
+62.86% 26.45B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-19.79% 14.69B
INCYTE CORPORATION Stock Incyte Corporation
-8.58% 12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.34% 11.54B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.92% 11.34B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.67% 8.84B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. IVBIY Stock
  5. Financials Innovent Biologics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW